Jinhua Bio (金河生物, SZ: 002688) is expanding its U.S. animal-health manufacturing footprint with planned investment of approximately US$31.92 million, targeting both veterinary pharmaceutical additives and vaccines.
The company’s board approved two projects through its U.S. subsidiaries: an expansion of the Pharmgate veterinary additive facility in Omaha and a new expansion project for its Pharmgate Biologics veterinary vaccine facility. The combined investment is estimated at US$31.9246 million, funded through company-owned or self-raised capital.
$5.9 Million Omaha Expansion
Approximately US$5.91 million is earmarked for the Omaha veterinary-additive plant.
The project includes expansion of the R&D laboratory, additional analytical and production equipment, and automation of the additive blending line. The company expects the project to take approximately 12 months.
A particularly important element is automation of packaging, coding and palletising operations. Jinhua Bio estimates that the upgrade could increase production capacity by approximately 2,000 tonnes per year.
The investment follows strong growth in Pharmgate’s U.S. veterinary pharmaceutical business. According to Jinhua Bio’s disclosure, Pharmgate’s consolidated first-half 2026 revenue increased by RMB80.08 million, or 19.94% year on year, while veterinary chemical-pharmaceutical revenue increased 25.74%. Chlortetracycline has been an important contributor to the U.S. business.
$26 Million Veterinary Vaccine Expansion
The larger component is a planned US$26.02 million investment in expansion of the U.S. veterinary vaccine facility, including lease-related expenditure.
This takes the total U.S. investment to roughly:
| Project | Investment |
|---|---|
| Omaha veterinary-additive expansion | US$5.91M |
| U.S. veterinary vaccine expansion | US$26.02M |
| Total | US$31.92M |
The allocation is strategically significant: approximately 81.5% of the planned investment is directed toward vaccines, while about 18.5% goes toward veterinary pharmaceutical/additive capacity.
Why the U.S. Matters to Jinhua Bio
Jinhua Bio has been building an international animal-health platform rather than relying exclusively on the Chinese market.
Its 2026 interim report describes an established U.S. operating presence and notes that overseas business has become an increasingly important contributor to revenue and profit. The company has also developed veterinary vaccine capabilities through facilities in China and the United States.
The company currently reports 19 marketed veterinary vaccine products, spanning swine, ruminant and companion-animal applications, together with diagnostic reagents and technical services.
The U.S. investment therefore represents more than simple capacity expansion. It strengthens local manufacturing, product development and supply-chain positioning in one of the world’s largest animal-health markets.
Analyst View: A Shift Toward Localized Manufacturing
The investment comes at a time when animal-health manufacturers increasingly face pressure to establish regional production and supply-chain resilience. For Jinhua Bio, U.S.-based capacity can provide several potential advantages:
-
shorter supply chains for North American customers;
-
greater manufacturing flexibility;
-
additional production capacity for growing veterinary-product demand;
-
closer integration of R&D and quality-control activities with U.S. operations;
-
reduced dependence on cross-border shipment of finished products;
-
stronger positioning for future product registrations.
The Omaha project is particularly notable because it combines manufacturing automation with laboratory expansion rather than simply adding physical production space. That suggests a strategy focused on both productivity and new-product development.
Broader Animal-Health Strategy
Jinhua Bio’s international expansion is also occurring alongside continued investment in its broader animal-health portfolio.
Its 2026 interim report states that the company has four major production bases—in Inner Mongolia, Hangzhou, the United States and Jilin—and two R&D centres, including a U.S. research centre. Its technology platforms include antigen industrialisation, antigen purification, antigen quantitative detection and recombinant-subunit antigen development.
The company also reported RMB1.448 billion in first-half 2026 revenue, with veterinary chemical pharmaceuticals contributing approximately RMB877 million and veterinary biological products approximately RMB127.45 million.
That makes the U.S. expansion strategically relevant to a company whose core business remains veterinary pharmaceuticals but which is attempting to increase the contribution of biologics and diversify across animal-health categories.
Bottom Line
Jinhua Bio’s US$31.92 million U.S. investment is a meaningful step in the company’s international animal-health strategy. The relatively modest Omaha investment is focused on automation and capacity productivity, while the much larger vaccine project signals an ambition to build a stronger U.S.-based biologics platform.
For the global veterinary pharmaceutical market, the development reflects a wider trend toward localized manufacturing, regional supply-chain resilience and expansion of veterinary biologics—particularly vaccines—as animal-health companies seek greater access to major markets.
